Antibodies to glutamic acid decarboxylase-65 (GAD65) are present in autoimmune disorders such as insulin-dependent (type1) diabetes mellitus (IDDM), stiff man syndrome, and polyendocrine autoimmune disease. Autoantibodies to GAD65 are present in 60-70% of individuals with newly diagnosed IDDM, and thus are important markers for disease activity. These autoantibodies usually recognize conformation-dependent regions on GAD65 and rarely bind to the second isoform, GAD67. Autoantibodies to GAD67 are found in only 15% of recent-onset IDDM patients, and most of this binding can be blocked with GAD65, suggesting shared epitopes between the two isoforms of GAD.
This antibody is specific for the 65-kDa isoform of glutamic acid decarboxylase (GAD65), targeting the IDDM-E2 region (amino acids 451-570), and does not bind the second isoform, GAD67. To create this cell line, peripheral blood B-cells were obtained from a donor who tested positive for GAD65 autoantibodies and were immortalized with Epstein-Barr virus. It has been conjugated to biotin via an amide bond.
Applications include immunoblotting, immunoprecipitation, immunohistochemistry, and protein footprinting.
Other GAD65 Products:
GAD65 (B78) Human Monoclonal (Cat. #AB-N12) | biotin-labeled (Cat. #AB-N12BT) | Alexa488-labeled (Cat. #AB-N12FLA)
GAD65 (B96) Human Monoclonal (Cat. #AB-N13) | biotin-labeled (Cat. #AB-N13BT) | Alexa488-labeled (Cat. #AB-N13FLA)